What is ENGN (ENGN) stock price today?

ENGN (ENGN) is currently trading at $1.79, up 1.7% today.

What is ENGN P/E ratio?

ENGN's P/E ratio is -0.70. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is ENGN return on equity (ROE)?

ENGN's return on equity (ROE) is -69.64%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is ENGN's market cap?

ENGN has a market capitalization of $91.64M.

NASDAQ · Biotechnology

ENGN (ENGN) Stock

$1.79 +1.70% NASDAQ: ENGN Healthcare

Valuation

Metric	Value
Price	$1.79
Market Cap	$91.64M
P/E Ratio	-0.70
P/B Ratio	0.49
P/S Ratio	0.00
EPS (TTM)	$-2.29
52-Week High	$12.25
52-Week Low	$1.40
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-69.64%
ROA	-52.94%
ROCE	-73.65%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.12
Current Ratio	6.28

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-16.0M	$-19.0M	$-26.0M	$-62.0M	$-123.0M
Net Profit	$-23.0M	$-24.0M	$-100.0M	$-55.0M	$-117.0M
EPS	$-0.01	$0.00	$-4.24	$-1.46	$-2.29
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$131.0M	$132.0M	$87.0M	$311.0M	$221.0M
Total Liabilities	$4.0M	$5.0M	$14.0M	$39.0M	$54.0M
Cash	$1.0M	$0	$82.0M	$173.0M	$50.0M
Borrowings	$0	$0	$10.0M	$25.0M	$32.0M

Latest News

enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones Business Wire · Jul 16, 2026 Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman GlobeNewswire · Jul 15, 2026 Sector Update: Healthcare Stocks Decline Late Afternoon MT Newswires · Jun 18, 2026 Neumora depression drug fails; EnGene to cut 50% of staff BioPharma Dive · Jun 16, 2026 enGene Reports Second Quarter 2026 Financial Results and Provides Business Update Business Wire · Jun 15, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-16.0M	$-18.0M	$-25.0M	$-48.0M	$-99.0M
Investing Cash Flow	$0	$0	$-1.0M	$-127.0M	$-27.0M
Financing Cash Flow	$0	$0	$-4.0M	$-7.0M	$0
Net Cash Flow	$6.0M	$9.0M	$61.0M	$91.0M	$-123.0M
Free Cash Flow	$-16.0M	$-18.0M	$-25.0M	$-49.0M	$-101.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	—
FCF Yield	-125.92%
Quick Ratio	11.75
Interest Coverage	-41.00
Return 1Y	-46.58%
Return 3Y	-82.57%
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ACIU	$2.31	+0.22%	-4.04	$234.59M	0.00%
ALT	$3.03	-1.30%	-2.31	$267.42M	0.00%
AMRNAmarin Corporation plc	$14.58	+0.80%	-9.00	$301.45M	0.00%
ANNX	$5.37	+0.75%	-3.71	$879.83M	0.00%
ANRO	$28.67	+0.70%	-6.29	$1.01B	0.00%

About ENGN

ENGN is led by CEO Ronald H. W. Cooper, employs 56 people, headquartered in CA, publicly traded since 2022.

ENGN stock trades at $1.79 with a market capitalization of $91.64M. The stock is valued at a price-to-earnings (P/E) ratio of -0.70, price-to-book of 0.49, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.40 and $12.25, and currently trades 85.4% below its 52-week high.

On profitability, ENGN generates a return on equity (ROE) of -69.64%, return on capital employed of -73.65%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides